Muscle Specific Fragile X Related Protein 1 Isoforms are Sequestered in the Nucleus of Undifferentiated Myoblast by Dubé, Marthe et al.
BMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
BMC Genetics (2000) 1:4 Research article
Muscle Specific Fragile X Related Protein 1 Isoforms are 
Sequestered in the Nucleus of Undifferentiated Myoblast
Marthe Dubé, Marc-Etienne Huot and Edouard W Khandjian
Address:  Unité de Recherche en Génétique Humaine et Moléculaire, Hôpital Saint François d'Assise du CHUQ, Québec, (Qc) G1L 3L5 and 
Département de biologie médicale, Faculté de médecine, Université Laval, Québec, Canada.
E-mail: Marthe Dubé - miracle_marthe@hotmail.com Marc-Etienne Huot - squall_98@hotmail.com Edouard W Khandjian - 
edward.khandjian@crsfa.ulaval.ca 
Abstract
Background:  The family of Fragile X Mental Retardation Proteins is composed of three members:
Fragile Mental Retardation 1, Fragile X Related 1 and X Related 2 proteins. These proteins are
associated with mRNPs within translating ribosomes and have the capacity to shuttle between the
nucleus and the cytoplasm. Great attention has been given to FMRP due to its implication in human
hereditary mental retardation while FXR1P and FXR2P have only recently been studied.
Results:  Using antibodies directed against several epitopes of FXR1P, we have detected protein
isoforms generated by small peptides pocket inserts. Four isoforms of MW 70, 74, 78, 80 kDa are
widely distributed in mouse organs, while in striated muscles these isoforms are replaced by
proteins of 82 and 84 kDa containing an extra pocket of 27 aa. Expression of these muscle isoforms
is an early event during in vitro differentiation of myoblasts into myotubes and correlates with the
activation of muscle-specific genes. However, while FXR1P82,84 are associated with cytoplasmic
mRNPs in myotubes, they are sequestered in the nuclei of undifferentiated myoblasts. These
observations suggest that, in addition to a cytoplasmic function yet to be defined, FXR1P82,84 may
play a nuclear role in pre-mRNA metabolism.
Conclusions:  The pattern of subcellular partitioning of FXR1P isoforms during myogenesis is
unique  among  the  family  of  the  FXR  proteins.  The  model  system  described here should  be
considered as a powerful tool for ongoing attempts to unravel structure-function relationships of
the different FMR family members since the potential role(s) of FXR1P as a compensatory factor
in Fragile X syndrome is still elusive.
Background
The Fragile X Mental Retardation (FMR) protein family
is composed of three highly homologous members. The
Fragile X Mental Retardation Protein (FMRP) is coded
by the X-linked FMR1 gene and its absence is directly as-
sociated with human hereditary mental retardation [re-
viewed in 1,2]. Two other members of this family are the
Fragile X Related 1 (FXR1P) and Fragile X Related 2
(FXR2P) proteins [3,4,5] that are coded by the FXR1 and
FXR2 genes located at 3q28 and 17p13.1, respectively, in
human. These genes are highly conserved in vertebrate
evolution and contain two KH domains and a RGG box
that are functional characteristic motifs in RNA-binding
proteins [4,5,6,7]. In addition, they also contain a nucle-
ar localization signal (NLS) as well as a nuclear export
signal (NES) making them putative nucleocytoplasmic
shuttling proteins [reviewed in 1,2]. Finally, FMRP as
well as the other members of the family have been shown
to be associated with messenger RiboNucleoParticles
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(mRNP) within actively translating ribosomes. This as-
sociation suggests that their roles might be linked to
RNA transport and/or translation [8,9,10,11,12].
Whereas absence of FMRP is the cause of Fragile X Men-
tal Retardation in human, it is not known whether
FXR1P and FXR2P are associated to any pathology or
phenotype. Also it is not known whether these homolo-
gous proteins can compensate for the absence of FMRP
in the case of the Fragile X syndrome. In vitro studies
showed that all three members interact with themselves
and with each other [5, 13, 14]. However, their distribu-
tion in certain mouse and human tissues showed individ-
ual pattern of expression [15, 16] indicating that each
protein also may function autonomously [17].
FXR1P has been shown to have a complex expression
pattern in different mammalian cell lines since six dis-
tinct isoforms were observed and their respective levels
were shown to be cell type specific [12]. In particular, it
was observed that 4 distinct FXR1P isoforms of MW 70
and 74 kDa (previously referred to as short) and 78 and
80 kDa (long) are widely expressed in diverse cell lines as
well as in different organs in mouse. However, in muscle,
these isoforms are replaced by novel super long isoforms
of MW 82 and 84 kDa. The replacement of the short and
long isoforms by the super long isoforms is clearly appar-
ent during myogenesis of myoblastic cell lines that can
differentiate in vitro into myotubes. This model system
which mimics, although imperfectly, muscle differentia-
tion has permitted us to show in the present report that
transition of the short and long isoforms to the super
long is an early event that takes place concomitantly to
the expression of muscle-specific genes. In addition, we
also show that low levels of the super long isoforms are
constitutively expressed in undifferentiated myoblasts
and that they are sequestered in the nuclei, while in dif-
ferentiated myotubes P82,84 are transferred to the cyto-
plasm where they are incorporated in mRNPs present in
actively translating ribosomes.
Results
Complex expression of FXR1P isoforms
Initial reports of FXR1 cloning described the presence of
two mRNA variants [3,4] while recent analyses showed
that at least 7 mRNA variants can be detected [18]. These
alternatively spliced mRNA differ each from other by the
presence or absence of four different exon sequences. A
virtual representation of the corresponding deduced
protein isoforms is shown in Figure 1. For the identifica-
tion of the different proteins corresponding to the differ-
ent mRNA variants (iso a to iso g) we used the
numbering of Kirkpatrick et al. [18]. For convenience,
the different proteins are illustrated in order of decreas-
ing length. All of the seven FXR1P isoforms contain the
same unmodified region from amino acids 1 to 379 after
which the addition or lack of different small peptide
pocket inserts are due to alternative spliced mRNA vari-
ants. Addition of 87, 78 and 81 nucleotides inserts in dif-
ferent mRNA directs the synthesis of 29, 26, and 27 extra
amino acid pockets, (exon 12, 13 and 15 boxes in Figure
1b) respectively. A fourth spliced variant of 92 nucle-
otides induces a frameshift that results in the addition of
30 amino acids and a C-terminal with a final product of
677 amino acid long protein. When the 92 nucleotides
sequence is absent, a stop codon at bases 1878-1880 of
the mRNA allows the synthesis of only 5 additional ami-
no acids and the C-terminal is thus truncated (Figure 1b).
We have previously described two antibodies, mAb3FX
and rabbit polyclonal serum #830, that detect different
FXR1P isoforms [12]. To obtain new antibodies to the
muscle specific isoforms, two synthetic polypeptides cor-
responding to stretches in the 27 aa sequence present in
the muscle super long FXR1P isoforms [12,18] were used
Figure 1
Schematic representation of the FXR1 protein structure. a)
Localization of the RNA-binding domains (KH and RGG; yel-
low) and the nuclear localization (NL) and export (NE) sig-
nals (green). b) Structure of the different FXR1P isoforms at
the C-termini generated by the four small peptide inserts (in
blue) deduced from the sequence of individual mRNA vari-
ants  according  to  Kirkpatrick's  et  al.  [18]  numbering  and
after  compilation  of  GenPept  access  No  AF124386.1  to
124394.1. The boxes (exon 12, 13, 15 and 16, in blue) corre-
spond to the peptide inserts present or absent in the differ-
ent  protein  isoforms.  The  red  zones  indicate  the  regions
recognized by the different antibodies.BMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
to immunize rabbits. Two polyclonal sera #27-15 and
#27-17 were obtained. The different regions that are rec-
ognized by the antibodies are shown in Figure 1b. In the-
ory, mAb3FX should have reacted with the 7 isoforms,
however because of the differences of 1 to 3 amino acids
between iso c, iso f and iso g (650, 648 and 651 aa) it was
not possible to resolve these proteins by SDS-PAGE. The
specificity of the antibodies to the different FXR1P iso-
forms as well as the distribution of the different isoforms
in several mouse tissues is shown in Figure 2. A complex
distribution of the 70, 74, 78, and 80 kDa isoforms is ob-
served using mAb3FX. In agreement with previous ob-
servations [12] none of these isoforms are detected in
muscle and heart extracts. Instead, super long isoforms
of 82 and 84 kDa are present in these tissues. These ob-
servations were clearly confirmed with the use of anti-se-
rum #830 which detects the 78, 80, 82 and 84 kDa
isoforms and also with #27-15 and #27-17 sera that are
specific to the 82 and 84 kDa isoforms. The additionnal
band detected at 94 kDa with mAb3FX corresponds to
the closely homologous Fragile X Related 2 protein [5]
recognized by this monoclonal antibody since part of the
peptide used for immunization is present in FXR2P.
To compare P82,84 in heart and muscle, protein extracts
prepared from these tissues were subjected to two-di-
mension gel electrophoresis followed by immunoblot
analyses using #27-15 antiserum. P82,84 appear to un-
dergo major post-translational modifications and three
variants with pI 6.0, 5.7 and 5.4 were detected for each
protein in both tissues, however with slight different dis-
tributions. Additional minor forms were also detected
around pI 6.6 (Figure 3). These results strongly suggest
that in these two tissues P82,84 have identical distribu-
tion. Indeed, in situ immunostaining of FXR1P in longi-
tudinal sections from adult mouse limb muscle and heart
with #27-15 (or #27-17) showed punctuated immunore-
active sites associated mainly with the myocontractile
structures (Figure 4). Identical staining patterns were
obtained with mAb3FX and #830 as previously shown
[12] since these antibodies also detect P82,84 while the
other FXR1P isoforms are absent in these tissues. Similar
if not identical pictures for mouse muscle were also re-
ported recently [16] with the use of a different antibody
(Ab2107). The distribution and specific punctuated fea-
tures of P82,84 staining in striated muscles are reminis-
cent of that seen for costameres structures containing
RNA and protein [19,20]. These structures lie between
the cell membrane and the Z line in skeletal and cardiac
muscles [21].
Accumulation of FXR1P82,84 isoforms during in vitro myo-
genesis
We have shown previously that the replacement of P70-
Figure 2
Distribution of FXR1P isoforms in extracts from different tis-
sues and organs in adult mouse. Equal amounts of proteins
(60 µ g) were resolved by SDS-PAGE (7.5% acrylamide) and
immunoblotted  with  three  antibodies  detecting  different
epitopes in FXR1P (see Results section). Note the specificity
of #27-15 antiserum to the FXR1P82,84 isoforms and the
cross-reaction of mAb3FX with FXR2P (94 kDa).BMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
80 by P82,84 correlates with differentiation of C2C4 my-
oblasts into myotubes after serum removal [12]. This
mouse myogenic cell line is derived from the original
skeletal muscle cell line C2 and is considered permissive
since it can readily differentiate in myotubes in medium
containing low serum concentrations [22]. To establish
more precisely the timing of the replacement of the short
and long isoforms by the super long, proteins were pre-
pared at different times after serum starvation and ana-
lyzed by immunoblotting. The kinetics of expression of
the different FXR1P isoforms is presented in Figure 5. In
non-differentiated myoblasts prominent bands were ob-
served at 70,74,78 and 80 kDa as well as the 94 kDa
FXR2P. As early as 24 h after induction, high levels of
P82,84 were detected while levels of the other FXR1P
isoforms started to decline. By three days after serum
deprivation, P82,84 levels reached a maximum plateau
and only faint bands corresponding to the other isoforms
were detected. A better picture was obtained using anti-
serum #27-15 specific to the super long isoforms and un-
expectedly allowed us to detect low levels of P82,84 in
non-differentiated myoblasts. The results presented
above clearly showed that increased accumulation of
P82,84 has taken place during the first 24 h after serum
starvation at a time when no morphological changes are
detected at the microscopic level. To test for the hypoth-
esis that the induction of P82,84 is an early event that is
directly linked to the initial commitment of myoblasts to
differentiate into myotubes, protein extracts were pre-
pared at different times over a period of 24 h after serum
depletion. Immunoblot analyses showed that trace
amounts of P82,84 were present in undifferentiated my-
oblasts. Increasing levels of P82,84 were detected as ear-
ly as 12-15 h (Figure 6 upper panels). At this time,
accumulation of muscle specific factors of the regulatory
program that controls myogenesis, such as myogenin,
began to increase [23]. Cardiac Troponin T levels also be-
gan to increase around 12 h while a decrease in nestin
levels was observed in agreement with earlier observa-
tions made on different cell lines induced to differentiate
into myotubes [24,25]. Finally, desmin levels remained
constant during the early period studied (not shown),
since its accumulation is a late event during myogenesis
[24].
Figure 3
Two-dimensional immunoblot analysis of proteins extracted
from heart and limb muscle from adult mouse. Hundred and
fifty µ g of protein extracts were resolved by IEF in the first
dimension and by 7.5% SDS-PAGE in the second dimension.
Arrows indicate the positions of the major P82,84 modified
variants at pH 6.0, 5.7 and 5.4.
Figure 4
Comparative immunostaining of FXR1P82,84 in mouse heart
and limb muscle. The red staining deposits indicate the locali-
z a t i o n  o f  P 8 2 , 8 4  i n  s t r i a t e d  m u s c l e  a s  d o t - l i k e  s t r u c t u r e s
reminiscent of costameres associated with Z bands. Nuclei
were counterstained with hematoxylin. Scale bars: = 10 µ m.BMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
Based on the observations reported above, we tested
whether accumulation of P82,84 was regulated at the
level of its mRNA. Total RNA was extracted from undif-
ferentiated and from stimulated C2C4 myoblasts at dif-
ferent times and subjected to Northern blot analyses.
Membranes were sequentially probed with 32P-labeled
exon 15 and various cDNA inserts. The results presented
in Figure 6 (lower panels) representative of three inde-
pendent time-course analyses, showed that muscle spe-
cific exon 15 (81 nucleotides) hybridized to the two FXR1
transcripts of 3.2 and 2.4 kb [10,18]. In agreement with
the results obtained at the protein level, these mRNA
variants are present at low levels in non-differentiated
myoblasts. Densitometric analysis showed a clear and
significant increase (3.0 ±  0.5) of both transcripts at 15 h
after serum deprivation, then after their steady state lev-
els continued to augment to reach a 5 fold increase by 24
h. The beginning of this increase coincided in time with
that of myogenin and cardiac actin mRNAs, which began
to accumulate at 12-15 h. In contrast, myf 5 mRNA levels
decreased gradually as expected [26]. These results
clearly indicate that accumulation of the FXR1 mRNA
variants containing the muscle-specific exon 15 tightly
correlates with the activation of muscle-specific genes.
FXR1P82,84 are absent from polyribosomes in undifferen-
tiated myoblasts
Given the association of FXR1P with mRNPs present in
polyribosomes [12], we asked whether all the different
FXR1P isoforms would be found present in mRNP en-
gaged in the translational machinery. Post-nuclear su-
pernatants were prepared from non-induced myoblasts
as well as from myotubes at day 3 after serum depriva-
tion and analyzed by sedimentation velocity through su-
crose density gradients. Immunoblot analyses of each
collected fraction using the different antibodies to
FXR1P showed that in extracts from non-induced cells,
FXR1P70,74,78,80 co-fractionated with light polyribos-
omes, while in extracts prepared from myotubes,
P70,74,78,80 and P82,84 were detected in heavier sedi-
menting structures (Figure 7). Further evidence that the
FXR1P82,84 isoforms were associated with mRNP en-
gaged in polyribosomes was obtained after treatment of
these structures with EDTA that causes dissociation of
ribosomes into their large and small subunits and the re-
lease of the associated mRNPs. After such a treatment,
P82,84 were recovered as heterogeneous slower sedi-
menting structures with the majority peaking around
60-70 S (Figure 7). These results indicate that similarly
to their closely related homologues FMRP and FXR2P,
all FXR1P members are also associated with mRNPs
within the translational machinery.
In repeated analyses using the highly specific antibodies
#27-15 and #27-17, we were unable to detect P82,84 in
polyribosomes and in mRNPs extracted from myoblasts
(Figure 7). This was puzzling since these isoforms were
constantly detected in total protein extracts (see Figures
5 and 6) and we hypothesized that P82,84 would have
been retained in the 10 000 x g pellet during the prepa-
ration of the cytoplasmic extracts. Indeed, crude prepa-
rations of nuclear and cytoplasmic fractions from
myoblasts showed that P82,84 were recovered associat-
ed with the nuclear fraction while no signals were detect-
ed in the cytoplasm (Figure 8). In contrast, we estimated
that approximately 95% of P82,84 were present in the
cytoplasmic fraction in myotubes, while the remaining
5% were observed associated with the nuclear fractions.
Since the intensities observed in both nuclear prepara-
tions of myoblasts and myotubes were similar, these re-
sults indicate that equivalent amounts of FXR1P82,84
are present in nuclei regardless of the differentiation
Figure 5
Time course analyses of FXR1P isoforms levels in C2C4 cells
induced to differentiate. Equal amounts of proteins (approxi-
mately 40 µ g) from unstimulated myoblast (C: control) and
st imulat ed ce lls 1 to 3 d ay s afte r s erum de privation were
separated by SDS-PAGE and processed for immunoblot anal-
yses. All FXR1P isoforms were revealed with mAb3FX while
P82,84 were detected with #27-15. dps: days post-stimula-
tion.BMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
stage of the cells.
Nuclear localization of FXR1P82,84 in undifferentiated 
myoblasts
The results reported above clearly showed that the low
levels of FXR1P82,84 isoforms present in myoblasts are
not associated with polyribosomes and are recovered in
the nuclear pellet after cell lysis. These observations
prompted us to determine the in situ localization of
P82,84 in differentiated and undifferentiated C2C4 cells.
Immunofluorescent studies were performed using the
different antibodies to FXR1P. In myoblasts, a clear cyto-
plasmic staining was observed for P70,74,78,80 and for
P78,80 using mAb3FX and #830, respectively (Figure
9). Very faint signals were also observed at the level of
nuclei, and were confirmed to be intranuclear by confo-
cal microscopy (Figure 9 upper panels). Since P82,84
represent a very minor fraction of total FXR1P in myob-
lasts (see Figures 5 and 8) it was not possible to distinct
these isoforms with mAb3FX or #830 by immunofluo-
rescent reaction due to the strong cytoplasmic staining of
the other FXR1P isoforms. However, when antibody
#27-15 was used, a granular pattern of nucleoplasmic
distribution of P82,84 was observed as dot-like struc-
tures, which in some instances corresponded to DAPI
stained dots (Figure 9). It should be noted that pro-
longed exposure times were required to capture the in-
tranuclear images of P82,84. In cultures maintained in
low serum for 3 days, typical fused myotubes were ob-
served as elongated syncytia containing multiple nuclei
and a strong cytoplasmic staining of all isoforms includ-
ing P82,84 was observed in agreement with the results
obtained at the level of polyribosomes analyses (see Fig-
ure 7).
Discussion
Fragile X Related 1 protein belongs to the FMR family of
RNA binding proteins which are specifically associated
with mRNPs engaged in actively translating ribosomes.
All members of this family share the same protein struc-
ture and contain key domains that are conserved in RNA
binding proteins [reviewed in 27] as well as NL and NE
signals which allow the proteins to shuttle between the
cytoplasm and the nucleus [8,28,29,30]. Indeed, accu-
mulation of the FMR proteins in the nucleus has been
observed experimentaly with truncated variants of the
proteins [28,30] as well as after overexpression experi-
ments followed by treatment with Leptomycin B, an an-
tibiotic that inhibits the nuclear export of NES-
containing proteins [31,32]. Due to extensive alternative
splicing of the FMRP primary transcript [33,34], it is be-
lieve that at least 20 different FMRP isoforms might ex-
ist. However, using the available antibodies, only 6
FMRP variants have been observed [35,36,37]. Similarly
to FMR1, FXR1 primary transcript undergoes complex
alternative splicing, however yielding in theory a much
more modest number of protein isoforms. Recent studies
[18] showed that 7 mRNA variants are detected, and our
analyses in mouse organs revealed that unlike FMRP, the
different FXR1P isoforms are tissue-specific. In general,
P70,74,78,80 are widely expressed, albeit at different
levels, and their respective ratio seem to be cell and tis-
sue specific. In heart and skeletal muscle, these short and
long protein isoforms are absent and are replaced by the
P82,84 super long isoforms that are generated by a small
peptide insert of 27 aa [12].
While FMRP is abundant in neurons, it is absent in mus-
cle [12,35]. On the other hand, FXR1P82,84 specific to
muscle has not been detected in neurons or in brain ex-
tracts [12 and this study]. This tissue specificity is not
maintained in culture of undifferentiated myoblasts
since both FMRP and P82,84 are detected in these cells
[12]. In addition, P70,74,78,80 isoforms which are ab-
sent in muscle are clearly present in myoblasts. These
observations suggest that the individual FMR members
may be interchangeable in certain physiological condi-
tions such as cell deadaptation in culture [38] or under
cellular reprogramming during wound healing [35]. Us-
ing the model system of myoblast induced to differenti-
ate into myotubes, we provide evidence that expression
of the non-muscle to muscle-specific isoforms of FXR1P
correlates with cellular differentiation. We observed that
the levels of P82,84 and that of muscle mRNA variants
begin to increase at an early time after stimulation con-
comitant with the expression of different markers of my-
ogenesis. Accumulation of these super long isoforms is
paralleled by the decrease of the short and long isoforms
and finally at day 3 when approximately 80% of the cells
underwent myotube differentiation, P82,84 accounted
for the great majority of FXR1P. These results strongly
suggest that the mechanisms by which FXR1P82,84 ex-
pression are controlled, reside at the level of splicing of
the primary transcript. Further analyses are required to
determine the factors associated with the expression of
these muscle mRNA variants.
In undifferentiated myoblasts, P82,84 make exception in
the FMR protein family since they are not associated
with polysomal mRNPs and are sequestered in the nucle-
us. One possible explanation for this localization would
have been that these isoforms contain, in addition to the
canonical NLS found in all FMR protein members, a sec-
ond nuclear localization signal. In fact, Tamanini et al.
[39] recently reported that the 27 aa pocket insert con-
tains a short arginine rich motif (QRRNRSRRR) identi-
cal to amino acids 35 to 44 present in a domain thatBMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
confers nucleolar localization to the HIV Rev protein
[40]. Although a similar (PQRRNRSRRRRFRGQ) pep-
tide present in the 27 aa pocket, when coupled to a dye,
has been shown to penetrate the cell and target the nu-
cleolus [39], transient expression of all FXR1P isoforms,
with or without the 27 aa pocket, localize exclusively to
the cytoplasm [39 and our unpublished results]. Thus, it
is not established that localization of FXRP82,84 is un-
der the control of this peptide sequence. On the other
hand, proteins that have been considered to be strictly
nucleoplasmic, such as the hnRNPs [27] or the Rev pro-
teins [41], have subsequently been found to shuttle be-
tween the nucleus and the cytoplasm [42,43,44,45]. In
addition, hnRNPs have been shown to participate in the
processing of pre-mRNAs and in the transport of mRNAs
to the cytoplasm, and have even been suggested to play a
role in translational regulation [46,47,48]. We propose
that FXR1P82,84 might be sequestered in nucleoplasmic
complexes in undifferentiated myoblasts and once cells
are committed to differentiate, P82,84 are transferred to
the cytoplasm with mRNPs carrying the newly processed
mRNAs specific to the differentiated stage of myotubes.
According to our working hypothesis, a nuclear role, yet
to be defined, for FXR1P82,84 in undifferentiated myob-
lasts, is conceivable.
Conclusions
Previous studies on the FMR proteins have shown that
although the FXR1 protein is predominantly cytoplas-
mic, in rare occasions a nuclear localization has been ob-
served in undifferentiated cells in several tissues of
human foetuses and mouse embryo [15,49]. The model
system of C2C4 myoblasts that can be manipulated in
vitro to differentiate into myotubes provides strong evi-
dence that specific isoforms of FXR1P are indeed seques-
tred in the nucleus in undifferentiated myoblasts. As a
working hypothesis we propose that the pattern of nu-
cleo-cytoplasmic partitioning of FXR1P isoforms is un-
der the control of factors regulating cell differentiation.
By extention, we also speculate that isoforms of FMRP,
that for the moment have escaped detection due to the
very restricted number of available antibodies, might
play a nuclear role in mRNA maturation at specific stag-
es of neuronal differentiation and plasticity. In conclu-
sion, the model system described here should be
considered as a powerful tool for ongoing attempts to un-
ravel structure-function relationships of the different
FMR family members since the potential role(s) of
FXR1P and FXR2P as a compensatory factor(s) in Frag-
ile X Mental Retardation is still elusive.
Figure 6
Accumulation of FXR1P82,84 is an early event and coincides
with expression of different myogenetic markers. Protein (40
µ g) and RNA (5  µ g) were prepared at the indicated times
and subjected to immunoblot (Western) and Northern anal-
y s e s ,  r e s p e c t i v e l y .  E x p o s u r e  t i m e s  f o r  W e s t e r n  a n a l y s e s
were between 15 and 30 sec. Northern blots were exposed
for 36 h while the 81 bp insert required prolonged exposure
up to 72 h due to the short probe used. hps: hours post-
stimulation after serum deprivation.BMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
Material and Methods
Cell culture
The mouse myogenic cell line C2C4, a subclone of the
mouse skeletal muscle cell line C2, [22] was obtained
from Chistian Pinset, Institut Pasteur, Paris, France.
Cultures were routinely maintained at low cell density in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 20% fetal calf serum (FCS) plus antibiotics
(100 units/ml penicillin, 50 µ g/ml streptomycin). Cul-
tures were usually initiated with 3 ×  104 cells in 100-mm
diameter petri dishes. After 4 days of culture, differenti-
ation was induced by replacing the medium with DMEM
containing 0.2% FCS.
Protein studies
Two synthetic polypeptides of 15 (DDSEKKPQR-
RNRSRR) and 17 (NRSRRRRFRGQAEDRQP) amino ac-
ids present in the muscle peptide insert of 27 aa [12] were
synthesized on a branched lysine residue (MAP carrier
core technique by Research Genetic, Huntsville, Ala-
bama) and used for immunization of rabbits using stand-
ard protocols and two polyclonal sera #27-15 and #27-17
were obtained. The monoclonal antibody 3FX and the
polyclonal #830 anti-serum that detect different
epitopes, have been described previously [12].
Total proteins from cell cultures and from various mouse
tissues were prepared as described [37]. Immunodetec-
tion analyses were performed using the following anti-
bodies: mAb3FX and #830 [12], #27-15 and #27-17 (this
study) for FXR1P. Hybridoma supernatants for cardiac
troponin T (CT3; developed by JJ-C Lin), myogenin
(F5D; WE Wright), nestin (Rat-401; S Hockfield), and
desmin (D3; DA Fischman) were obtained from the De-
velopmental Studies Hybridoma Bank developed under
the auspices of the NICHD and maintained by The Uni-
versity of Iowa, Department of Biological Sciences, Iowa
City, IA 52242 (http://www.uiowa.edu/~dshbwww/).
Immunoreaction was detected using horse radish perox-
Figure 7
FXR1P  isoforms  are  associated  with  mRNPs  present  in
polyribosomes. Aliquots containing ~12 A260 units of post-
nuclear supernatants from non-induced myoblasts and from
differentiated myotubes at day 3 were analyzed by sedimen-
tation velocity through sucrose density gradients. Each col-
lected  fraction  from gradients containing  MgCl2 o r  E DT A
(lower panels) was analyzed for the presence of all FXR1P
isoforms using three different antibodies. Note that none of
the  antibodies  used  detect  P82,84  in cytoplasmic  extracts
from myoblasts.
Figure 8
Low levels of FXR1P82,84 are present in nuclear preparation
of  undifferentiated  myoblasts  and  differentiated  myotubes,
while in differentiated myotubes, accumulation of P82,84 is
restricted  to  the  cytoplasmic  fraction.  N:  nuclear,  and  C:
cytoplasmic fractions, respectively.BMC Genetics (2000) 1:4 http://www.biomedcentral.com/1471-2156/1/4
idase-conjugated secondary antibodies followed by the
ECL (Amersham Pharmacia Biotech) reaction and expo-
sure to Kodak Biomax MR films. High resolution two-di-
mension gel electrophoresis was conducted essentially as
described [50] with the following modifications. The first
IEF dimension contained 9 M urea, 2% Ampholynes pH
3.5-10 (Amersham Pharmacia Biotech AB) and 2% of
CHAPS (Sigma, St Louis, MO) instead of 2% NP-40, and
electrophoresis was conducted for 14 000 V/h under a
constant current of 300 V. The second SDS-PAGE di-
mension consisted of a 7.5% acrylamide gel. Distribution
of the different FXR1P isoforms in nuclear, cytoplasmic
and polyribosome fractions were conducted as described
previously [10] in the presence of Complete™, Mini (Ro-
che Diagnostics) protease inhibitors cocktail.
RNA studies
Total RNA was prepared using the Trizol reagent (GIB-
CO). Northern blot analyses were performed as de-
scribed [51]. RNA was estimated by optical density at
260 nm and corrected for even loading (5 µ g) after dot
blot hybridization with a 32P-labeled 18S rRNA probe
followed by radioactivity determination by liquid scintil-
lation counting. cDNA inserts for myogenin, myf5 [52],
and cardiac actin [53] were 32P-labeled by random prim-
ing. To obtain a specific probe to FXR1 exon 15, the 81 bp
was cloned in pCR®II plasmid and amplified by PCR us-
ing as primers CAGGAAACAGCTATGACC (forward) and
ATACGACTCACTATAGGG (reverse). The short 297 bp
fragment obtained was labeled by random priming. Den-
sitometric analyses were performed on autoradiograms
using the NIH Image 1.62f program.
Immunofluorescence microscopy and immunohistochemis-
try
Immunoreactions on cells grown on glass coverslips and
on sections from mouse organs were performed as previ-
ously described [12]. Fluorescent and light microscopy
were viewed with a Nikon TE300 microscope connected
to a CoolSnap camera (RS Photometrics) using a 100 x
oil immersion objective. Confocal images were obtained
with a Zeiss LSM-310 microscope and images were
colored using the Adobe PhotoShop program.
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